Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer

Inclusion Criteria:

• Diagnosed as gastric adenocarcinoma by pathology and had not received any otheranti-tumor treatment such as radiotherapy and chemotherapy;
• ≥ 18 and ≤ 70 years of age; Eastern Cooperative Oncology Group Performance Status (ECOG): 0-1;
• Intraoperative pathological diagnosis was peritoneal metastasis (stage ≤ P1b), with orwithout ascites (ascites volume exceeding pelvic cavity but not reaching fullabdominal ascites)
• Patients have adequate baseline organ and marrow function :hemoglobin≥9g/dL; absoluteneutrophil count (ANC) ≥1,500/mm3; PLT(platelets)≥1000,000/mm3; total bilirubin ≤1.5×upper normal limit(ULN); AST ≤2.5 ×ULN, ALT ≤2.5 ×ULN; prothrombintime-international normalized ratio≤1.5, and APTT(activated partial thromboplastintime) was within normal range; creatine ≤ 1.5 x ULN;
• Written informed consent provided;

Exclusion Criteria:

• Diagnosed as Her-2(+++)/FISH(+) by pathology;
• With other distant metastasis(ovarian metastasis was excluded)
• Patients with Serious liver disease (such as cirrhosis, etc.), kidney disease,respiratory disease or uncontrolled diabetes, hypertension and other chronic systemicdiseases, heart disease with Clinical symptoms, such as congestive heart failure,coronary heart disease symptoms, drug is difficult to control arrhythmia,hypertension, or six months had a myocardial infarction attack, or cardiacinsufficiency;
• Organ transplantation patients need immunosuppressive therapy;
• Severe recurrent infections were not controlled or with other serious concomitantdiseases;
• Patients got other primary malignant tumors (except curable skin basal cell carcinomaand cervical cancer in situ) except gastric cancer within 5 years; Psychiatric diseasewhich require treatment;
• Within 6 months before study starts and in the process of this study, patientsparticipate in other clinical researches;
• Patients with peripheral nervous system disorder or apparent mental disorders or hadthe history of central nervous system disorders;
• Pregnant or lactating women, women of child-bearing potential, unwilling to useadequate contraceptive protection during the process of the study;
• Patients without legal capacity,or medical/ethical reasons may influence the study tocontinue.